Cytokine therapy or structured treatment interruptions in HIV infection: which is best?
Continuous highly active antiretroviral therapy (HAART) is the treatment of choice for HIV patients in order to prevent opportunistic infection or AIDS-related morbidity and mortality. However, new HIV treatment strategies are needed to face the emerging problems related to long-term toxicities and failures of HAART. Moreover, total eradication and complete restoration of immune system function cannot be achieved by HAART alone. Therefore, in an attempt to increase the natural immunity of HIV-infected patients, immune-based therapies have been investigated. This review is intended to provide an update on the use of immune-based therapies, in particular structured treatment interruptions and cytokines, such as IL-2 and IFN-alpha, as potential stimulants of the immune system of patients with HIV-infections and to discuss risks and benefits of each alternative. Ongoing and future clinical trials will provide a rationale for their use in clinical practice and will determine how these strategies can be combined to optimise HAART.
Parienti
Jean-Jacques
JJ
Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Côte de Nacre, Caen, France.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000191:economics; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use
D019380:Anti-HIV Agents; D016207:Cytokines; D016898:Interferon-alpha; D007376:Interleukin-2